Trial Profile
Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2014
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 01 Feb 2014 Interim results presented at the 2014 Genitourinary Cancers Symposium.
- 01 Feb 2014 Status changed from active, no longer recruiting to discontinued.
- 02 Apr 2013 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.